Cargando…

Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan

Clinical isolates of drug-resistant (isoniazid and/or rifampicin-resistant) Mycobacterium tuberculosis were obtained from 254 patients diagnosed with drug-resistant tuberculosis in Japan from April 2015 to March 2017 in National Hospital Organization hospitals. The 254 patients were approximately 32...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizukoshi, Fuminori, Kobayashi, Nobuyuki, Kirikae, Fumiko, Ohta, Ken, Tsuyuguchi, Kazunari, Yamada, Noritaka, Inoue, Yoshikazu, Horiba, Masahide, Kawata, Noriko, Ichinose, Akiko, Miyoshi-Akiyama, Tohru, Kiritani, Reiko, Funatogawa, Keiji, Kirikae, Teruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386464/
https://www.ncbi.nlm.nih.gov/pubmed/34232083
http://dx.doi.org/10.1128/mSphere.00978-20
_version_ 1783742268156411904
author Mizukoshi, Fuminori
Kobayashi, Nobuyuki
Kirikae, Fumiko
Ohta, Ken
Tsuyuguchi, Kazunari
Yamada, Noritaka
Inoue, Yoshikazu
Horiba, Masahide
Kawata, Noriko
Ichinose, Akiko
Miyoshi-Akiyama, Tohru
Kiritani, Reiko
Funatogawa, Keiji
Kirikae, Teruo
author_facet Mizukoshi, Fuminori
Kobayashi, Nobuyuki
Kirikae, Fumiko
Ohta, Ken
Tsuyuguchi, Kazunari
Yamada, Noritaka
Inoue, Yoshikazu
Horiba, Masahide
Kawata, Noriko
Ichinose, Akiko
Miyoshi-Akiyama, Tohru
Kiritani, Reiko
Funatogawa, Keiji
Kirikae, Teruo
author_sort Mizukoshi, Fuminori
collection PubMed
description Clinical isolates of drug-resistant (isoniazid and/or rifampicin-resistant) Mycobacterium tuberculosis were obtained from 254 patients diagnosed with drug-resistant tuberculosis in Japan from April 2015 to March 2017 in National Hospital Organization hospitals. The 254 patients were approximately 32% of all 795 patients who were diagnosed with culture-confirmed drug-resistant tuberculosis from 2015 to 2016 nationwide in Japan. The whole-genome sequences of all the isolates from the 254 patients and the lineages of these isolates were determined, and phylogenetic trees were constructed based on single nucleotide polymorphism concatemers. Of these patients, 202 (79.5%) were born in Japan and 52 (20.5%) were born elsewhere. Of the 254 drug-resistant isolates, 54 (21.3%) were multidrug resistant, being resistant to both isoniazid and rifampicin. The percentages of multidrug-resistant isolates were significantly higher in foreign-born (38.5% [20/52]) than Japanese-born patients (16.8% [34/202]). Of the 54 multidrug-resistant isolates, nine were extensively drug resistant, which were all obtained from Japanese-born patients. Five extensively drug-resistant isolates were obtained from patients with incipient tuberculosis. A significant number of multidrug-resistant M. tuberculosis strains were isolated from foreign-born patients from Asian countries that have a high tuberculosis burden. Foreign-derived isolates affect the nationwide genetic diversity of drug-resistant M. tuberculosis in Japan. Extensively drug-resistant M. tuberculosis isolates were transmitted among the Japanese population. IMPORTANCE The incidence rate of tuberculosis (TB) in Japan was 11.5 per 100,000 of the population in 2019. Of TB patients in Japan, 61.1% were aged >70 years, and 10.7% were born outside Japan, mostly in Asian countries with a high burden of tuberculosis. Of the tuberculosis patients in the present study, 5.4% and 1.0% showed resistance to isoniazid and rifampicin, respectively, and 0.7% were multidrug resistant. The objective of this study was to clarify the molecular epidemiological properties of drug-resistant tuberculosis in Japan. Molecular epidemiology provides several clues to inform potential measures to control drug-resistant tuberculosis in Japan.
format Online
Article
Text
id pubmed-8386464
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-83864642021-09-09 Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan Mizukoshi, Fuminori Kobayashi, Nobuyuki Kirikae, Fumiko Ohta, Ken Tsuyuguchi, Kazunari Yamada, Noritaka Inoue, Yoshikazu Horiba, Masahide Kawata, Noriko Ichinose, Akiko Miyoshi-Akiyama, Tohru Kiritani, Reiko Funatogawa, Keiji Kirikae, Teruo mSphere Research Article Clinical isolates of drug-resistant (isoniazid and/or rifampicin-resistant) Mycobacterium tuberculosis were obtained from 254 patients diagnosed with drug-resistant tuberculosis in Japan from April 2015 to March 2017 in National Hospital Organization hospitals. The 254 patients were approximately 32% of all 795 patients who were diagnosed with culture-confirmed drug-resistant tuberculosis from 2015 to 2016 nationwide in Japan. The whole-genome sequences of all the isolates from the 254 patients and the lineages of these isolates were determined, and phylogenetic trees were constructed based on single nucleotide polymorphism concatemers. Of these patients, 202 (79.5%) were born in Japan and 52 (20.5%) were born elsewhere. Of the 254 drug-resistant isolates, 54 (21.3%) were multidrug resistant, being resistant to both isoniazid and rifampicin. The percentages of multidrug-resistant isolates were significantly higher in foreign-born (38.5% [20/52]) than Japanese-born patients (16.8% [34/202]). Of the 54 multidrug-resistant isolates, nine were extensively drug resistant, which were all obtained from Japanese-born patients. Five extensively drug-resistant isolates were obtained from patients with incipient tuberculosis. A significant number of multidrug-resistant M. tuberculosis strains were isolated from foreign-born patients from Asian countries that have a high tuberculosis burden. Foreign-derived isolates affect the nationwide genetic diversity of drug-resistant M. tuberculosis in Japan. Extensively drug-resistant M. tuberculosis isolates were transmitted among the Japanese population. IMPORTANCE The incidence rate of tuberculosis (TB) in Japan was 11.5 per 100,000 of the population in 2019. Of TB patients in Japan, 61.1% were aged >70 years, and 10.7% were born outside Japan, mostly in Asian countries with a high burden of tuberculosis. Of the tuberculosis patients in the present study, 5.4% and 1.0% showed resistance to isoniazid and rifampicin, respectively, and 0.7% were multidrug resistant. The objective of this study was to clarify the molecular epidemiological properties of drug-resistant tuberculosis in Japan. Molecular epidemiology provides several clues to inform potential measures to control drug-resistant tuberculosis in Japan. American Society for Microbiology 2021-07-07 /pmc/articles/PMC8386464/ /pubmed/34232083 http://dx.doi.org/10.1128/mSphere.00978-20 Text en Copyright © 2021 Mizukoshi et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Mizukoshi, Fuminori
Kobayashi, Nobuyuki
Kirikae, Fumiko
Ohta, Ken
Tsuyuguchi, Kazunari
Yamada, Noritaka
Inoue, Yoshikazu
Horiba, Masahide
Kawata, Noriko
Ichinose, Akiko
Miyoshi-Akiyama, Tohru
Kiritani, Reiko
Funatogawa, Keiji
Kirikae, Teruo
Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
title Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
title_full Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
title_fullStr Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
title_full_unstemmed Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
title_short Molecular Epidemiology of Drug-Resistant Mycobacterium Tuberculosis in Japan
title_sort molecular epidemiology of drug-resistant mycobacterium tuberculosis in japan
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386464/
https://www.ncbi.nlm.nih.gov/pubmed/34232083
http://dx.doi.org/10.1128/mSphere.00978-20
work_keys_str_mv AT mizukoshifuminori molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT kobayashinobuyuki molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT kirikaefumiko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT ohtaken molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT tsuyuguchikazunari molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT yamadanoritaka molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT inoueyoshikazu molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT horibamasahide molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT kawatanoriko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT ichinoseakiko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT miyoshiakiyamatohru molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT kiritanireiko molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT funatogawakeiji molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan
AT kirikaeteruo molecularepidemiologyofdrugresistantmycobacteriumtuberculosisinjapan